Vir Biotechnology Inc VIR Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 15, 2021 (filed on Jan 19, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-10,530

Price:

--
Jan 15, 2021 (filed on Jan 19, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,530

Price:

$38.00
Jan 15, 2021 (filed on Jan 19, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

10,530

Price:

$1.53
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,805

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,805

Price:

$29.36
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,805

Price:

$1.53
Jan 04, 2021 (filed on Jan 05, 2021)

Insider Name:

Parrish Jay

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,945

Price:

$26.32
Jan 04, 2021 (filed on Jan 05, 2021)

Insider Name:

Parrish Jay

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

6,945

Price:

$1.49
Dec 24, 2020 (filed on Dec 28, 2020)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-9,500

Price:

--
Dec 24, 2020 (filed on Dec 28, 2020)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

9,500

Price:

$1.53

Filings by filing date

Jan 15, 2021 (filed on Jan 19, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-10,530

Price:

--
Jan 15, 2021 (filed on Jan 19, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,530

Price:

$38.00
Jan 15, 2021 (filed on Jan 19, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

10,530

Price:

$1.53
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,805

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,805

Price:

$29.36
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,805

Price:

$1.53
Dec 01, 2020 (filed on Jan 05, 2021)

Insider Name:

Parrish Jay

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,945

Price:

--
Jan 04, 2021 (filed on Jan 05, 2021)

Insider Name:

Parrish Jay

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,945

Price:

$26.32
Jan 04, 2021 (filed on Jan 05, 2021)

Insider Name:

Parrish Jay

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

6,945

Price:

$1.49
Dec 24, 2020 (filed on Dec 28, 2020)

Insider Name:

Virgin Herbert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-9,500

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	499 Illinois St Ste 500 SAN FRANCISCO CA 94158-2521
Tel:	N/A
Website:	https://www.vir.bio
IR:	See website

Key People

Vicki L. Sato Independent Chairman of the Board	George A. Scangos President, Chief Executive Officer, Director	Jay Parrish Chief Business Officer
Howard Horn Chief Financial Officer, Secretary	Herbert Whiting Virgin Executive Vice President of Research and Chief Scientific Officer	Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer

Business Overview

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Financial Overview

For the nine months ended 30 September 2020, VirBiotechnology Inc revenues increased from $7.1M to $74.6M.Net loss increased 74% to $193M. Revenues reflect Contractrevenue increase from $340K to $44.2M, Grant revenueincrease of 14% to $7.7M. Higher net loss reflects Researchand development increase from $93M to $206.9M (expense),General and administrative increase of 80% to $39M(expense).

Employees:	297 as of Sep 30, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$4,575M as of Sep 30, 2020
Annual revenue (TTM):	$75.61M as of Sep 30, 2020
EBITDA (TTM):	-$247.07M as of Sep 30, 2020
Net annual income (TTM):	-$256.79M as of Sep 30, 2020
Free cash flow (TTM):	-$153.45M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	127,388,620 as of Nov 6, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Vir Biotechnology Inc (OQ:VIR)